Tenofovir disoproxil Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0027 
C.I.z - Changes (Safety/Efficacy) of Human and 
06/06/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
N/0026 
Minor change in labelling or package leaflet not 
22/02/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IB/0025/G 
This was an application for a group of variations. 
29/08/2022 
SmPC, Annex 
C.I.2.a – To update section 5.1 of the SmPC in alignment 
II and PL 
with the reference product. 
C.I.11.a - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0024 
Minor change in labelling or package leaflet not 
06/05/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0023 
Transfer of Marketing Authorisation 
27/09/2021 
19/10/2021 
SmPC, 
Labelling and 
PL 
R/0022 
Renewal of the marketing authorisation. 
24/06/2021 
26/08/2021 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
IB/0021/G 
This was an application for a group of variations. 
22/03/2021 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
the CHMP considered that the benefit-risk balance of 
Tenofovir disoproxil Mylan in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0020/G 
This was an application for a group of variations. 
03/02/2021 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/01/2021 
26/08/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
12/11/2020 
11/01/2021 
SmPC, Annex 
Refer to Scientific conclusions and grounds recommending 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
202003 
tenofovir disoproxil 
II, Labelling 
the variation to terms of the Marketing Authorisation(s)’ for 
and PL 
PSUSA/2892/202003. 
IAIN/0017/G 
This was an application for a group of variations. 
27/03/2020 
11/01/2021 
Annex II and 
PL 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
14/11/2019 
13/01/2020 
SmPC 
Refer to Scientific conclusions and grounds recommending 
201903 
tenofovir disoproxil 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2892/201903. 
IB/0016 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
16/08/2019 
24/10/2019 
SmPC, 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/06/2019 
24/10/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0013/G 
This was an application for a group of variations. 
29/05/2019 
24/10/2019 
Annex II 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.11.a - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/03/2019 
24/10/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0011 
B.I.b.2.a - Change in test procedure for AS or 
14/01/2019 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0010/G 
This was an application for a group of variations. 
17/12/2018 
24/10/2019 
SmPC, 
Labelling and 
PL 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
31/10/2018 
n/a 
PRAC Recommendation - maintenance 
201803 
tenofovir disoproxil 
IAIN/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
24/10/2018 
24/10/2019 
SmPC 
Veterinary Medicinal Products - Other variation 
IB/0007/G 
This was an application for a group of variations. 
27/11/2017 
19/02/2018 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/2892/
Periodic Safety Update EU Single assessment - 
26/10/2017 
n/a 
PRAC Recommendation - maintenance 
201703 
tenofovir disoproxil 
IAIN/0006 
B.II.b.1.a - Replacement or addition of a 
10/08/2017 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0003 
B.II.e.5.a.2 - Change in pack size of the finished 
19/07/2017 
19/02/2018 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IA/0002 
B.II.b.2.a - Change to importer, batch release 
11/05/2017 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/03/2017 
19/02/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
